SVNT Insider Trading Activity and SEC Form 4 Filings
SVNT insider trading summary
No open-market insider purchases or sales of Savient Pharmaceuticals Inc (SVNT) have been reported on SEC Form 4 in the past 12 months.
Latest SVNT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 4, 2013 | Virgil Thompson | Director | Sell | $2K (106,751 @ $0.02) |
| Oct 17, 2013 | Stephen O Jaeger | Director | Sell | $2K (38,061 @ $0.05) |
| Oct 16, 2013 | Kenneth Bahrt | SVP, Chief Medical Officer | Sell | $176 (2,400 @ $0.07) |
| Oct 16, 2013 | Kenneth Bahrt | SVP, Chief Medical Officer | Sell | $36 (500 @ $0.07) |
| Oct 16, 2013 | Kenneth Bahrt | SVP, Chief Medical Officer | Sell | $116 (1,600 @ $0.07) |
| Oct 16, 2013 | Ginger Constantine | Director | Sell | $639 (8,805 @ $0.07) |
| Oct 16, 2013 | Kenneth Bahrt | SVP, Chief Medical Officer | Sell | $261 (3,500 @ $0.07) |
| Oct 15, 2013 | David Gionco | Chief Accounting Officer | Sell | $810 (10,000 @ $0.08) |
| Oct 15, 2013 | David Gionco | Chief Accounting Officer | Sell | $2K (20,900 @ $0.08) |
| Oct 15, 2013 | Kenneth Bahrt | SVP, Chief Medical Officer | Sell | $5K (65,639 @ $0.08) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.